Ocugen Inc. (OCGN)
0.72
-0.02 (-2.29%)
At close: Apr 25, 2025, 1:12 PM
-2.29% (1D)
| Bid | 0.72 |
| Market Cap | 211.71M |
| Revenue (ttm) | 4.05M |
| Net Income (ttm) | -54.05M |
| EPS (ttm) | -0.2 |
| PE Ratio (ttm) | -3.62 |
| Forward PE | -2.87 |
| Analyst | Buy |
| Ask | 0.73 |
| Volume | 1,707,779 |
| Avg. Volume (20D) | 3,802,622 |
| Open | 0.74 |
| Previous Close | 0.74 |
| Day's Range | 0.71 - 0.75 |
| 52-Week Range | 0.52 - 2.06 |
| Beta | 3.79 |
About OCGN
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 3, 2014
Employees 95
Stock Exchange NASDAQ
Ticker Symbol OCGN
Website https://www.ocugen.com
Analyst Forecast
According to 3 analyst ratings, the average rating for OCGN stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 865.52% from the latest price.
Stock Forecasts8 months ago
-7.8%
Ocugen shares are trading lower after the company ...
Unlock content with
Pro Subscription
8 months ago
-4.08%
Ocugen shares are trading lower after the company announced an underwritten public offering.
